From ELISA to Lateral Flow: Biotome’s Peptide Technology Delivers
- lukemarshall93
- 3 days ago
- 1 min read
Updated: 3 hours ago
Biotome has just completed its first feasibility study for a peptide-based lateral flow device targeting CagA-positive H. pylori—and the results exceeded expectations. Working with the experts at Beacon Scientific, we tested both competitive and sandwich assay formats.
The competitive assay showed strong, clean response curves. The sandwich assay? Sensitivity down to 0.3 nanograms per millilitre. To put that in perspective: we can detect the equivalent of a teaspoon of target diluted into an Olympic swimming pool.
What makes this particularly significant is what’s under the hood. Peptide-based diagnostics are notoriously challenging—peptides are small, finicky, and typically require coupling to carrier proteins to work in immunoassays. We took a different approach. Using our proprietary PepLock technology, we eliminated the carrier protein entirely. These results validate that PepLock works not just in ELISA formats, but now in lateral flow—a format built for low cost, point-of-care deployment, and massive manufacturing scale.
This milestone comes as we prepare to launch our first research-use-only ELISA kits next year, and it opens a clear path forward. Next up: testing with real patient samples.
CagA-positive H. pylori remains the primary driver of stomach cancer, the world’s third leading cause of cancer death, and most cases are preventable if caught early. Accurate, affordable, scalable diagnostics are how we get there.
